| Reference |
Sentence |
Publish Date |
Extraction Date |
Species |
| Wei Liu, Jingqi Zhou, Minjuan Cao, Fangming Zhang, Xiaoming Su. A pharmacokinetic analysis of amisulpride in adult Chinese patients with schizophrenia: Impact of creatinine clearance. International journal of clinical pharmacology and therapeutics vol issue 2023 36871243 |
a pharmacokinetic analysis of amisulpride in adult chinese patients with schizophrenia: impact of creatinine clearance. |
2023-03-05 |
2023-03-06 |
Not clear |
| Wei Liu, Jingqi Zhou, Minjuan Cao, Fangming Zhang, Xiaoming Su. A pharmacokinetic analysis of amisulpride in adult Chinese patients with schizophrenia: Impact of creatinine clearance. International journal of clinical pharmacology and therapeutics vol issue 2023 36871243 |
to develop a stable population pharmacokinetic (ppk) model of amisulpride and to investigate the effects of covariates on the pharmacokinetic parameters in adult chinese patients with schizophrenia. |
2023-03-05 |
2023-03-06 |
Not clear |
| Shuo Yang, HaiYan Wang, Gao Feng Zheng, Yi Wan. Age, Sex, and Comedication Effects on the Steady-State Plasma Concentrations of Amisulpride in Chinese Patients with Schizophrenia. Therapeutic drug monitoring vol issue 2023 36863030 |
age, sex, and comedication effects on the steady-state plasma concentrations of amisulpride in chinese patients with schizophrenia. |
2023-03-02 |
2023-03-06 |
Not clear |
| Shuo Yang, HaiYan Wang, Gao Feng Zheng, Yi Wan. Age, Sex, and Comedication Effects on the Steady-State Plasma Concentrations of Amisulpride in Chinese Patients with Schizophrenia. Therapeutic drug monitoring vol issue 2023 36863030 |
the effects of age, sex, or specific comedications on amisulpride concentrations in chinese patients with schizophrenia in the real world were investigated. |
2023-03-02 |
2023-03-06 |
Not clear |
| Ahmed M Abdelfattah, Sally A Abuelezz, Nevien Hendawy, Eman A Negm, Salwa Abd El Khalek Nawishy, Ahmed Mohamed Mohamed Khali. Sonic hedgehog pathway as a new target of atypical antipsychotics: Revisiting of amisulpride and aripiprazole effects in a rat model of schizophrenia. Life sciences vol issue 2023 36649751 |
sonic hedgehog pathway as a new target of atypical antipsychotics: revisiting of amisulpride and aripiprazole effects in a rat model of schizophrenia. |
2023-01-17 |
2023-01-30 |
rat |
| Ahmed M Abdelfattah, Sally A Abuelezz, Nevien Hendawy, Eman A Negm, Salwa Abd El Khalek Nawishy, Ahmed Mohamed Mohamed Khali. Sonic hedgehog pathway as a new target of atypical antipsychotics: Revisiting of amisulpride and aripiprazole effects in a rat model of schizophrenia. Life sciences vol issue 2023 36649751 |
in this study, effects of the anti-psychotics amisulpride and/or aripiprazole on the shh-pathway and its relation to cognitive functions and neurogenesis in a rat model of schizophrenia were tested. |
2023-01-17 |
2023-01-30 |
rat |
| Ze-Rui Hu, Zhen-Zhen Yang, Xu-Bo Wang, Hong-Shuo Chu, Chuan-Xin Li. Case report: Amisulpride therapy induced reversible elevation of creatine kinase-MB and bradycardia in schizophrenia. Frontiers in psychiatry vol 13 issue 2023 36590617 |
case report: amisulpride therapy induced reversible elevation of creatine kinase-mb and bradycardia in schizophrenia. |
2023-01-02 |
2023-01-30 |
Not clear |
| Ze-Rui Hu, Zhen-Zhen Yang, Xu-Bo Wang, Hong-Shuo Chu, Chuan-Xin Li. Case report: Amisulpride therapy induced reversible elevation of creatine kinase-MB and bradycardia in schizophrenia. Frontiers in psychiatry vol 13 issue 2023 36590617 |
amisulpride, a first-line atypical antipsychotic medication that acts as a blocker of the d2 and d3 dopamine receptors, is used in varying doses for the treatment of both positive and negative symptoms of schizophrenia. |
2023-01-02 |
2023-01-30 |
Not clear |
| Computational And Mathematical Methods In Medicin. Retracted: Changes of Mental State and Serum Prolactin Levels in Patients with Schizophrenia and Depression after Receiving the Combination Therapy of Amisulpride and Chloroprothixol Tablets. Computational and mathematical methods in medicine vol 2022 issue 2022 36561739 |
retracted: changes of mental state and serum prolactin levels in patients with schizophrenia and depression after receiving the combination therapy of amisulpride and chloroprothixol tablets. |
2022-12-23 |
2023-01-30 |
Not clear |
| Lieuwe de Haan, Mirjam van Tricht, Floor van Dijk, Celso Arango, Covadonga M D\\xc3\\xadaz-Caneja, Julio Bobes, Leticia Garc\\xc3\\xada-\\xc3\\x81lvarez, Stefan Leuch. Optimizing subjective wellbeing with amisulpride in first episode schizophrenia or related disorders. Psychological medicine vol issue 2022 36520136 |
optimizing subjective wellbeing with amisulpride in first episode schizophrenia or related disorders. |
2022-12-15 |
2023-01-30 |
Not clear |
| Correction to \"Amisulpride Augmentation of Clozapine in Clozapine-Resistant Schizophrenia: A Case Series\". The Canadian journal of hospital pharmacy vol 75 issue 4 2022 36246449 |
correction to "amisulpride augmentation of clozapine in clozapine-resistant schizophrenia: a case series". |
2022-10-17 |
2023-01-30 |
Not clear |
| Ming-Huan Zhu, Zhen-Jing Liu, Qiong-Yue Hu, Jia-Yu Yang, Ying Jin, Na Zhu, Ying Huang, Dian-Hong Shi, Min-Jia Liu, Hong-Yang Tan, Lei Zhao, Qin-Yu Lv, Zheng-Hui Yi, Feng-Chun Wu, Ze-Zhi L. Amisulpride augmentation therapy improves cognitive performance and psychopathology in clozapine-resistant treatment-refractory schizophrenia: a 12-week randomized, double-blind, placebo-controlled trial. Military Medical Research vol 9 issue 1 2022 36253804 |
amisulpride augmentation therapy improves cognitive performance and psychopathology in clozapine-resistant treatment-refractory schizophrenia: a 12-week randomized, double-blind, placebo-controlled trial. |
2022-10-17 |
2023-01-30 |
Not clear |
| Ming-Huan Zhu, Zhen-Jing Liu, Qiong-Yue Hu, Jia-Yu Yang, Ying Jin, Na Zhu, Ying Huang, Dian-Hong Shi, Min-Jia Liu, Hong-Yang Tan, Lei Zhao, Qin-Yu Lv, Zheng-Hui Yi, Feng-Chun Wu, Ze-Zhi L. Amisulpride augmentation therapy improves cognitive performance and psychopathology in clozapine-resistant treatment-refractory schizophrenia: a 12-week randomized, double-blind, placebo-controlled trial. Military Medical Research vol 9 issue 1 2022 36253804 |
the main purpose of this randomized, double-blind, placebo-controlled trial was to explore the amisulpride augmentation efficacy on the psychopathological symptoms and cognitive function of clozapine-resistant treatment-refractory schizophrenia (ctrs) patients. |
2022-10-17 |
2023-01-30 |
Not clear |
| Young Sup Woo, Sung-Yong Park, Bo-Hyun Yoon, Won-Seok Choi, Sheng-Min Wang, Won-Myong Bah. Amisulpride Augmentation in Schizophrenia Patients with Poor Response to Olanzapine: A 4-week, Randomized, Rater-Blind, Controlled, Pilot Study. Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology vol 20 issue 3 2022 35879041 |
amisulpride augmentation in schizophrenia patients with poor response to olanzapine: a 4-week, randomized, rater-blind, controlled, pilot study. |
2022-07-25 |
2023-01-30 |
Not clear |
| Yanqun Zheng, Xiaohua Liu, Mingliang J. A case of antipsychotic-induced psychomotor seizure. General psychiatry vol 35 issue 3 2022 35866001 |
the authors present a case of psychomotor seizure caused by amisulpride to treat schizophrenia. |
2022-07-22 |
2023-01-30 |
Not clear |
| Stephan Heres, Joachim Cordes, Sandra Feyerabend, Christian Schmidt-Kraepelin, Richard Musil, Michael Riedel, Ilja Spellmann, Berthold Langguth, Michael Landgrebe, Elmar Fran, Camelia Petcu C, Eric Hahn, Tam M T Ta, Valentin Matei, Liana Dehelean, Ion Papava, F Markus Leweke, Till van der List, Simona C Tamasan, Fabian U Lang, Dieter Naber, Stephan Ruhrmann, Claus Wolff-Menzler, Georg Juckel, Maria Ladea, Cristinel Stefanescu, Marion Lautenschlager, Michael Bauer, Daisy Zamora, Mark Horowitz, John M Davis, Stefan Leuch. Changing the Antipsychotic in Early Nonimprovers to Amisulpride or Olanzapine: Randomized, Double-Blind Trial in Patients With Schizophrenia. Schizophrenia bulletin vol issue 2022 35857811 |
changing the antipsychotic in early nonimprovers to amisulpride or olanzapine: randomized, double-blind trial in patients with schizophrenia. |
2022-07-20 |
2023-01-30 |
Not clear |
| Sukhpreet Poonia, Mazen Sharaf, Ric M Procyshyn, Randal White, Reza Rafizade. Amisulpride Augmentation of Clozapine in Clozapine-Resistant Schizophrenia: A Case Series. The Canadian journal of hospital pharmacy vol 75 issue 3 2022 35847467 |
amisulpride augmentation of clozapine in clozapine-resistant schizophrenia: a case series. |
2022-07-18 |
2023-01-30 |
Not clear |
| Lukasz Biernat, Vincent T Grattan, Mark S Hixon, Zachary Prensky, Andrew R Vain. A randomized, double-blind, placebo controlled, phase 1 study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of LB-102, a selective dopamine D Psychopharmacology vol issue 2022 35841422 |
a randomized, double-blind, placebo controlled, phase 1 study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of lb-102, a selective dopamine d lb-102 is an n-methylated analogue of amisulpride under development to treat schizophrenia. |
2022-07-16 |
2023-01-30 |
human |
| Kankan Qu, Qin Zhou, Lin Tian, Yuan Shen, Zhenhe Zho. Amisulpride steady-state plasma concentration and adverse reactions in patients with schizophrenia: a study based on therapeutic drug monitoring data. International clinical psychopharmacology vol issue 2022 35779068 |
amisulpride steady-state plasma concentration and adverse reactions in patients with schizophrenia: a study based on therapeutic drug monitoring data. |
2022-07-02 |
2023-01-27 |
Not clear |
| Kankan Qu, Qin Zhou, Lin Tian, Yuan Shen, Zhenhe Zho. Amisulpride steady-state plasma concentration and adverse reactions in patients with schizophrenia: a study based on therapeutic drug monitoring data. International clinical psychopharmacology vol issue 2022 35779068 |
the aim of the study was to evaluate the reference range of amisulpride for chinese patients with schizophrenia and to assess its possible influencing factors based on therapeutic drug monitoring information. |
2022-07-02 |
2023-01-27 |
Not clear |